TrimRx's Blog

Yes, Wegovy (semaglutide 2.4 mg) is FDA-approved for adolescents aged 12 and older with obesity, and Saxenda has been approved for teens since 2020.

The short answer is that no human study has tested this combination, so any claim of safety or efficacy is theoretical.

There is no FDA-approved dose for systemic injectable TB-500 because there is no FDA-approved indication.

TB-500 is a synthetic peptide based on a fragment of thymosin beta-4, a 43-amino-acid protein found naturally in nearly every cell of the human body.

There’s no FDA-approved taper protocol for semaglutide or tirzepatide. The label says to stop the medication, that’s it.

Switching from Zepbound to compounded tirzepatide is clinically simple when the compounded product uses tirzepatide base API at accurate potency.

Switching from Wegovy to compounded semaglutide is clinically straightforward. The active molecule is identical: semaglutide base.

Introduction Switching from Ozempic® to compounded semaglutide is straightforward if the compounded product uses semaglutide base API and the dose conversion is done carefully….

Introduction Switching from Mounjaro® to compounded tirzepatide works clinically when the compounded product uses tirzepatide base API and the dose conversion is handled carefully….